Predictors of symptomatic and asymptomatic intracranial atherosclerosis: What is different and why?

Journal of Atherosclerosis and Thrombosis

Volumn 21, Issue 6, 2014, Pages 605-617

  Kim, Bum Joon ^a   Hong, Keun Sik ^b   Cho, Yong Jin ^b   Lee, Ju Hun ^c   Koo, Ja Seong ^d   Park, Jong Moo ^e   Kang, Dong Wha ^a   Kim, Jong S ^a   Lee, Seung Hoon ^f   Kwon, Sun U ^a  

^a University of Ulsan   (South Korea)

^b Inje University   (South Korea)

^c Kangdong Sacred Heart Hospital   (South Korea)

^d The Catholic University of Korea   (South Korea)

^e Eulji General Hospital   (South Korea)

^f Seoul National University Hospital   (South Korea)

Author keywords

Atherosclerosis; Intracranial arteries; Predictors

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; CALCIUM CHANNEL BLOCKING AGENT; CILOSTAZOL; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; TETRAZOLE DERIVATIVE; VASODILATOR AGENT;

ADULT; AGED; ARTICLE; BRAIN ATHEROSCLEROSIS; CLINICAL EVALUATION; CLINICAL TRIAL (TOPIC); DISEASE COURSE; DISEASE SEVERITY; FEMALE; HUMAN; MAGNETIC RESONANCE ANGIOGRAPHY; MAJOR CLINICAL STUDY; MALE; REMISSION; RISK FACTOR; STENOSIS; ARTERY; ATHEROSCLEROSIS; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; INTRACRANIAL ARTERIOSCLEROSIS; MIDDLE AGED; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; REGRESSION ANALYSIS; STENOSIS, OCCLUSION AND OBSTRUCTION; TREATMENT OUTCOME;

AGED; ARTERIES; ATHEROSCLEROSIS; CHOLESTEROL, HDL; CONSTRICTION, PATHOLOGIC; DISEASE PROGRESSION; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INTRACRANIAL ARTERIOSCLEROSIS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; PROGNOSIS; REGRESSION ANALYSIS; RISK FACTORS; TETRAZOLES; TREATMENT OUTCOME; VASODILATOR AGENTS;

EID: 84903219206     PISSN: 13403478     EISSN: 18803873     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Mazighi M, Tanasescu R, Ducrocq X, Vicaut E, Bracard S, Houdart E, Woimant F: Prospective study of symptomatic atherothrombotic intracranial stenoses: the GESICA study. Neurology, 2006; 66: 1187-1191
2. Nahab F, Cotsonis G, Lynn M, Feldmann E, Chaturvedi S, Hemphill JC, Zweifler R, Johnston K, Bonovich D, Kasner S, Chimowitz M, Group WS: Prevalence and prognosis of coexistent asymptomatic intracranial stenosis. Stroke, 2008; 39: 1039-1041
3. Kern R, Steinke W, Daffertshofer M, Prager R, Hennerici M: Stroke recurrences in patients with symptomatic vs asymptomatic middle cerebral artery disease. Neurology, 2005; 65: 859-864
4. Kremer C, Schaettin T, Georgiadis D, Baumgartner RW: Prognosis of asymptomatic stenosis of the middle cerebral artery. J Neurol Neurosurg Psychiatry, 2004; 75: 1300-1303
5. Qureshi AI, Caplan LR: Intracranial atherosclerosis. Lancet, 2013
6. Burke AP, Kolodgie FD, Farb A, Weber DK, Malcom GT, Smialek J, Virmani R: Healed plaque ruptures and sudden coronary death: evidence that subclinical rupture has a role in plaque progression. Circulation, 2001; 103: 934-940
7. Falk E, Shah PK, Fuster V: Coronary plaque disruption. Circulation, 1995; 92: 657-671
8. Carr S, Farb A, Pearce WH, Virmani R, Yao JS: Atherosclerotic plaque rupture in symptomatic carotid artery stenosis. J Vasc Surg, 1996; 23: 755-765; discussion 765-756
9. Martinez-Sanchez P, Fernandez-Dominguez J, Ruiz-Ares G, Fuentes B, Alexandrov AV, Diez-Tejedor E: Changes in carotid plaque echogenicity with time since the stroke onset: an early marker of plaque remodeling? Ultrasound Med Biol, 2012; 38: 231-237
10. Teng Z, Degnan AJ, Sadat U, Wang F, Young VE, Graves MJ, Chen S, Gillard JH: Characterization of healing following atherosclerotic carotid plaque rupture in acutely symptomatic patients: an exploratory study using in vivo cardiovascular magnetic resonance. J Cardiovasc Magn Reson, 2011; 13: 64
11. Kwon SU, Hong KS, Kang DW, Park JM, Lee JH, Cho YJ, Yu KH, Koo JS, Wong KS, Lee SH, Lee KB, Kim DE, Jeong SW, Bae HJ, Lee BC, Han MK, Rha JH, Kim HY, Mok VC, Lee YS, Kim GM, Suwanwela NC, Yun SC, Nah HW, Kim JS: Efficacy and safety of combination antiplatelet therapies in patients with symptomatic intracranial atherosclerotic stenosis. Stroke, 2011; 42: 2883-2890
12. Kasner SE, Chimowitz MI, Lynn MJ, Howlett-Smith H, Stern BJ, Hertzberg VS, Frankel MR, Levine SR, Chaturvedi S, Benesch CG, Sila CA, Jovin TG, Romano JG, Cloft HJ, Warfarin Aspirin Symptomatic Intracranial Disease Trial I: Predictors of ischemic stroke in the territory of a symptomatic intracranial arterial stenosis. Circulation, 2006; 113: 555-563
13. Berry C, Noble S, Gregoire JC, Ibrahim R, Levesquie S, Lavoie MA, L'Allier PL, Tardif JC: Glycaemic status influences the nature and severity of coronary artery disease. Diabetologia, 2010; 53: 652-658
14. Hirohata A, Yamamoto K, Miyoshi T, Hatanaka K, Hirohata S, Yamawaki H, Komatsubara I, Murakami M, Hirose E, Sato S, Ohkawa K, Ishizawa M, Yamaji H, Kawamura H, Kusachi S, Murakami T, Hina K, Ohe T: Impact of olmesartan on progression of coronary atherosclerosis a serial volumetric intravascular ultrasound analysis from the OLIVUS (impact of OLmesarten on progression of coronary atherosclerosis: evaluation by intravascular ultrasound) trial. J Am Coll Cardiol, 2010; 55: 976-982
15. Folsom AR, Eckfeldt JH, Weitzman S, Ma J, Chambless LE, Barnes RW, Cram KB, Hutchinson RG: Relation of carotid artery wall thickness to diabetes mellitus, fasting glucose and insulin, body size, and physical activity. Atherosclerosis Risk in Communities (ARIC) Study Investigators. Stroke, 1994; 25: 66-73
16. Stumpe KO, Agabiti-Rosei E, Zielinski T, Schremmer D, Scholze J, Laeis P, Schwandt P, Ludwig M, investigators Ms: Carotid intima-media thickness and plaque volume changes following 2-year angiotensin II-receptor blockade. The Multicentre Olmesartan atherosclerosis Regression Evaluation (MORE) study. Ther Adv Cardiovasc Dis, 2007; 1: 97-106
17. Hink U, Li H, Mollnau H, Oelze M, Matheis E, Hartmann M, Skatchkov M, Thaiss F, Stahl RA, Warnholtz A, Meinertz T, Griendling K, Harrison DG, Forstermann U, Munzel T: Mechanisms underlying endothelial dysfunction in diabetes mellitus. Circ Res, 2001; 88: E14-22
18. Kishi T, Hirooka Y, Konno S, Sunagawa K: Angiotensin II receptor blockers improve endothelial dysfunction associated with sympathetic hyperactivity in metabolic syndrome. J Hypertens, 2012; 30: 1646-1655
19. Lewis GF, Rader DJ: New insights into the regulation of HDL metabolism and reverse cholesterol transport. Circ Res, 2005; 96: 1221-1232
20. Johnsen SH, Mathiesen EB, Fosse E, Joakimsen O, Stensland-Bugge E, Njolstad I, Arnesen E: Elevated highdensity lipoprotein cholesterol levels are protective against plaque progression: a follow-up study of 1952 persons with carotid atherosclerosis the Tromso study. Circulation, 2005; 112: 498-504
21. Tardif JC, Gregoire J, L'Allier PL, Ibrahim R, Lesperance J, Heinonen TM, Kouz S, Berry C, Basser R, Lavoie MA, Guertin MC, Rodes-Cabau J, Effect of r HDLoA-S, Efficacy I: Effects of reconstituted high-density lipoprotein infusions on coronary atherosclerosis: a randomized controlled trial. JAMA, 2007; 297: 1675-1682
22. Sviridov D, Mukhamedova N, Remaley AT, Chin-Dusting J, Nestel P: Antiatherogenic functionality of high density lipoprotein: how much versus how good. J Atheroscler Thromb, 2008; 15: 52-62
23. Taylor AJ, Burke AP, Farb A, Yousefi P, Malcom GT, Smialek J, Virmani R: Arterial remodeling in the left coronary system: the role of high-density lipoprotein cholesterol. J Am Coll Cardiol, 1999; 34: 760-767
24. Takase H, Hashimoto A, Okutsu R, Hirose Y, Ito H, Imaizumi T, Miyakoda G, Mori T: Anti-atherosclerotic effect of cilostazol in apolipoprotein-E knockout mice. Arzneimittelforschung, 2007; 57: 185-191
25. Chen WJ, Chen YH, Lin KH, Ting CH, Yeh YH: Cilostazol promotes vascular smooth muscles cell differentiation through the cAMP response element-binding protein-dependent pathway. Arterioscler Thromb Vasc Biol, 2011; 31: 2106-2113
26. Kang S, Wu Y, Li X: Effects of statin therapy on the progression of carotid atherosclerosis: a systematic review and meta-analysis. Atherosclerosis, 2004; 177: 433-442
27. Chimowitz MI, Lynn MJ, Derdeyn CP, Turan TN, Fiorella D, Lane BF, Janis LS, Lutsep HL, Barnwell SL, Waters MF, Hoh BL, Hourihane JM, Levy EI, Alexandrov AV, Harrigan MR, Chiu D, Klucznik RP, Clark JM, McDougall CG, Johnson MD, Pride GL Jr, Torbey MT, Zaidat OO, Rumboldt Z, Cloft HJ Investigators ST: Stenting versus aggressive medical therapy for intracranial arterial stenosis. N Engl J Med, 2011; 365: 993-1003
28. Shimizu K, Shimomura K, Tokuyama Y, Sakurai K, Isahaya K, Takaishi S, Kato B, Usuki N, Shimizu T, Yamada K, Hasegawa Y: Association between Inflammatory Biomarkers and Progression of Intracranial Large Artery Stenosis after Ischemic Stroke. J Stroke Cerebrovasc Dis, 2013; 22: 211-217
29. Yamada K, Fujimoto Y: Efficacy of cilostazol for intracranial arterial stenosis evaluated by digital subtraction angiography/ magnetic resonance angiography. Adv Ther, 2011; 28: 866-878
30. Paciaroni M, Eliasziw M, Sharpe BL, Kappelle LJ, Chaturvedi S, Meldrum H, Barnett HJ: Long-term clinical and angiographic outcomes in symptomatic patients with 70% to 99% carotid artery stenosis. Stroke, 2000; 31: 2037-2042